# Extended-Release Tacrolimus Following Liver Transplantation

> **NCT05242315** · PHASE4 · RECRUITING · sponsor: **University of Alberta** · enrollment: 94 (estimated)

## Conditions studied

- Liver Transplant; Complications
- Renal Insufficiency
- Immunosuppressant Adverse Reaction
- Metabolic Syndrome
- Cardiovascular Diseases

## Interventions

- **DRUG:** Envarsus Oral Product
- **DRUG:** Prograf (SOC)

## Key facts

- **NCT ID:** NCT05242315
- **Lead sponsor:** University of Alberta
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-05-15
- **Primary completion:** 2026-12-15
- **Final completion:** 2034-02-15
- **Target enrollment:** 94 (ESTIMATED)
- **Last updated:** 2025-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05242315

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05242315, "Extended-Release Tacrolimus Following Liver Transplantation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05242315. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*